Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-3232
Title: Risk factors for indeterminate interferon-gamma release assay for the diagnosis of tuberculosis in children : a systematic review and meta-analysis
Authors : Meier, Noëmi R.
Volken, Thomas
Geiger, Marc
Heininger, Ulrich
Tebruegge, Marc
Ritz, Nicole
Published in : Frontiers in Pediatrics
Volume(Issue) : 7
Issue : 208
Publisher / Ed. Institution : Frontiers
Issue Date: 2019
License (according to publishing contract) : CC BY 4.0: Attribution 4.0 International
Type of review: Peer review (publication)
Language : English
Subjects : Clinical study; IGRA; Latent; Pediatrics; Risk difference; QuantiFERON; T-SPOT.TB; T cell response
Subject (DDC) : 616: Internal medicine and diseases
Abstract: Background: Interferon-gamma release assays (IGRA) are well-established immunodiagnostic tests for tuberculosis (TB) in adults. In children these tests are associated with higher rates of false-negative and indeterminate results. Age is presumed to be one factor influencing cytokine release and therefore test performance.The aim of this study was to systematically review factors associated with indeterminate IGRA results in pediatric patients. Methods: Systematic literature review guided by the preferred reporting items for systematic reviews and meta-analyses (PRISMA) searching PubMed, EMBASE, and Web of Science. Studies reporting results of at least one commercially available IGRA (QuantiFERON-TB, T-SPOT.TB) in pediatric patient groups were included. Random effects meta-analysis was used to assess proportions of indeterminate IGRA results. Heterogeneity was assessed using the I2 value. Risk differences were calculated for studies comparing QuantiFERON-TB and T-SPOT.TB in the same study.Meta-regression was used to further explore the influence of study level variables on heterogeneity. Results: Of 1,293 articles screened, 133 studies were included in the final analysis. These assessed QuantiFERON-TB only in 77.4% (103/133), QuantiFERON-TB and T-SPOT.TB in 15.8% (21/133), and T-SPOT.TB only in 6.8% (9/133) resulting in 155 datasets including 107,418 participants. Overall 4% of IGRA results were indeterminate, and T-SPOT.TB (0.03, 95% CI 0.02–0.05) and QuantiFERON-TB assays (0.05, 95% CI 0.04–0.06) showed similar proportions of indeterminate results; pooled risk difference was−0.01 (95% CI −0.03 to 0.00). Significant differences with lower proportions of indeterminate assays with T-SPOT.TB compared to QuantiFERON-TB were only seen in subgroup analyses of studies performed in Africa and in non-HIV-infected immunocompromised patients. Meta-regression confirmed lower proportions of indeterminate results for T-SPOT.TB compared to QuantiFERON-TB only among studies that reported results from non-HIV-infected immunocompromised patients (p < 0.001). Conclusion: On average indeterminate IGRA results occur in 1 in 25 tests performed. Overall, there was no difference in the proportion of indeterminate results between both commercial assays. However, our findings suggest that in patients in Africa and/or patients with immunocompromising conditions other than HIV infection the T-SPOT.TB assay appears to produce fewer indeterminate results.
Departement: Health Professions
Organisational Unit: Institute of Health Sciences (IGW)
Publication type: Article in scientific journal
DOI : 10.21256/zhaw-3232
10.3389/fped.2019.00208
ISSN: 2296-2360
URI: https://digitalcollection.zhaw.ch/handle/11475/17228
Appears in Collections:Publikationen Gesundheit

Files in This Item:
File Description SizeFormat 
fped-07-00208.pdf8.02 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.